An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.

摘要: Abstract OBJECTIVES: The nitrogen-containing bisphosphonates alendronate and risedronate have been reported to upper gastrointestinal (GI) safety tolerability profiles comparable those of placebo. Nevertheless, both agents demonstrated similar potential for irritation gastric mucosa at high doses in preclinical studies. present study compared the produce endoscopic GI mucosal using highest approved dosage regimens two agents. METHODS: This was a multicenter, randomized, parallel-group, double-blind, placebo-controlled trial which total 235 patients (men or postmenopausal women, aged 45–80 yr) with normal endoscopy baseline received 28-day treatments following: 40 mg/day (N = 90), 30 89), placebo 36), aspirin 650 mg q.i.d. last 7 days 20). Endoscopy repeated on day 29 standardized scoring scales. RESULTS: After 28 treatment, groups had mean duodenal erosion scores that were significantly lower than group. Esophageal all groups. Gastric ulcers and/or large numbers erosions occurred approximately 3% versus 60% aspirin. Both clinically well tolerated. CONCLUSIONS: gastroduodenal is markedly less findings this study, together clinical experience extensive epidemiological data alendronate, suggest risk important these very low, even available doses.